Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication

N/ANot Yet RecruitingNCT07130253

National Taiwan University Hospital220 enrolled

Overview

1. This study aims to compare the efficacy of empirical vonoprazan-based therapy versus susceptibility-guided vonoprazan-based therapy for third-line eradication of H. pylori. 2. We also plan to explore the impact of eradication therapy on gut microbiota, fecal antibiotic resistance, and metabolic parameters before and after treatment.

Methods: * Study design: Open-labeled, randomized controlled trial * Participants: A total of 220 patients who have failed at least two previous H. pylori eradication treatments will be enrolled. Determination of antibiotic resistance of H. pylori: Agar dilution test will be used to determine the minimum inhibitory concentrations of levofloxacin, tetracycline, rifabutin, and clarithromycin to guide the selection of antibiotics. Treatment regimens and assignment: Eligible patients will be randomized to receive either one of the treatments (A) Empirical vonoprazan-based therapy or (B) Susceptibility-guided vonoprazan-based therapy Outcome Measurement: Primary End Point: Eradication rate by intention-to-treat analysis. Secondary End Point: 1. Eradication rate by per-protocol analysis; 2. Frequency of adverse effects.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

220

Conditions

HELICOBACTER PYLORI INFECTIONS

Interventions

Vonoprazan based ETDRUG

Empirical therapy Based on drug history: Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or quadruple therapy

Vonoprazan based SGTDRUG

Susceptibility testing guided therapy Based onsusceptibility test:Levofloxacin sequential therapy or bismuth quadruple therapy (10 or 14 days) or rifabutin quadruple therapy

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Helicobacter pylori infected individuals who have failed at least two previous eradication therapies. 2. Willing to undergo third-line eradication therapy. 3. Subjects must be 20 years of age or older. Exclusion Criteria: 1. History of gastrectomy. 2. Individuals unsuitable for the study medication, such as those with a history of allergy or severe adverse reactions to the study drugs, quinolone or fluoroquinolone antibiotics, or women who are pregnant or breastfeeding. 3. Presence of severe acute or chronic diseases such as renal failure, liver cirrhosis, incurable malignant tumors, or a history of aortic aneurysm or dissection. 4. Patients with chronic hepatitis (AST or ALT \> 100 U/L). 5. Unwillingness to comply with the treatment plan or sign the informed consent form.

Locations (1)

National Taiwan University Hospital

Taipei, Taiwan

Outcomes

Primary Outcomes

Eradication rate by intention-to-treat analysis

Eradication rate will be determined by urea breath test at least 6 weeks aftercompletion of treatment.

Time frame: 6-8 weeks

Secondary Outcomes

Eradication rate by per-protocol analysis and Frequency of adverse effects.

Eradication rate will be determined by urea breath test at least 6 weeks aftercompletion of treatment. A standard interview and questionaire will be used to assess the adverse effects.

Time frame: 6-8 weeks

Central Contacts

Mei-Jyh Chen, MD, PhD

CONTACT

886-2-23123456 Ext. 265427 migichen@ntuh.gov.tw

Yu-Chun Huang

CONTACT

nneder34@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.